导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.08% | 1401/4773 |
| 近一周 | -1.17% | 2225/5467 |
| 近一月 | -11.76% | 5110/5421 |
| 近一季 | -20.62% | 4853/5238 |
| 近半年 | 1.40% | 1300/4931 |
| 近一年 | 6.34% | 1414/4400 |
| 近两年 | 120.16% | 416/2954 |
| 近三年 | 69.94% | 342/2253 |
| 成立以来 | 278.18% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.35% 1766/4961 |
37.23% 851/5312 |
- - |
- - |
| 2025 | 51.81% 425/4813 |
-1.73% 2765/3635 |
3.30% 1059/4076 |
50.71% 294/4524 |
-0.77% 2634/4813 |
| 2024 | 13.98% 1085/3463 |
-4.01% 1599/2808 |
-6.63% 1988/3014 |
29.30% 165/3129 |
-1.65% 1781/3463 |
| 2023 | -19.14% 1846/2656 |
2.16% 1424/2280 |
-7.20% 1806/2385 |
-9.58% 1855/2515 |
-5.68% 1456/2655 |
| 2022 | -29.23% 1595/2207 |
-20.01% 1516/1919 |
5.97% 800/2016 |
-18.55% 1722/2113 |
2.50% 914/2208 |
| 2021 | 12.34% 386/1822 |
-7.08% 1056/1255 |
26.50% 70/1330 |
-6.64% 972/1466 |
2.37% 611/1822 |
| 2020 | 65.64% 94/1250 |
4.03% 92/1028 |
30.91% 45/1067 |
5.55% 910/1164 |
15.23% 224/1184 |
| 2019 | 44.30% 174/1092 |
35.13% 99/754 |
-10.19% 724/804 |
7.66% 82/850 |
10.43% 134/918 |
| 2018 | -28.65% 442/834 |
- - |
- - |
- - |
-10.85% 233/691 |
| 2017 | -10.65% 536/714 |
- - |
- - |
- - |
- - |
| 2016 | -26.07% 487/605 |
- - |
- - |
- - |
- - |
| 2015 | 78.05% 1/575 |
- - |
- - |
- - |
- - |
| 2014 | 11.82% 205/237 |
- - |
- - |
- - |
- - |
| 2013 | 78.51% 1/186 |
- - |
- - |
- - |
- - |
| 2012 | -2.13% 132/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 易方达创业板ETF VS. 长安沪深300非周期A(740101) |